Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for Moderate-to-Severe COPD with Type 2 Inflammation
NCT03930732Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2019
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of dupilumab in chronic obstructive pulmonary disease (COPD), sponsored by Sanofi. Started Apr 2019; status: completed.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03930732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03930732.